Nutraplus India Hits Rock Bottom: ₹0.14 Cr Q3 Loss, Revenue Vanishes

Standalone Net Loss: ₹0.14 Cr (Q3 FY21)
Standalone Total Revenue: ₹0.03 Cr (Q3 FY21)
Reader Takeaway: Losses widened on asset seizure; terminal state of business operations remains high.

What just happened (today’s filing)

Nutraplus India Ltd. has reported a dire financial performance for the quarter ended December 31, 2020 (Q3 FY21) and the year ended March 31, 2020 (FY20).

For the December 2020 quarter, standalone total revenue plummeted to ₹3.28 Lakhs (₹0.03 Cr), while total expenses stood at ₹17.15 Lakhs (₹0.17 Cr). This resulted in a net loss of ₹13.87 Lakhs (₹0.14 Cr) and an Earnings Per Share (EPS) of (₹0.04).

The year-on-year revenue growth for the quarter was a staggering -99.85%, collapsing from ₹2,190.17 Lakhs in the comparable prior period to just ₹3.28 Lakhs.

Annual results for the year ended March 31, 2020, show a total revenue of ₹10,681.16 Lakhs (₹106.81 Cr) against total expenses of ₹15,463.78 Lakhs (₹154.64 Cr), leading to a substantial net loss of ₹4,782.62 Lakhs (₹47.83 Cr) and an EPS of (₹14.03).

Why this matters

The company's management has explicitly stated that the 'Going Concern' concept is 'completely vitiated' and there is 'no hope' for any restructuring plan. This indicates that the company is facing existential threats and may not be able to continue its operations in the foreseeable future.

Combined with the seizure of all its property, plants, and equipment under the SARFESIA Act, this paints a picture of a business in a terminal state of financial failure. The auditors' qualified review report further underscores significant governance and compliance issues.

The backstory (grounded)

Nutraplus India Ltd. has been grappling with severe financial distress for some time. It was declared a Non-Performing Asset (NPA) in FY 2019-20, leading to the seizure of its assets under the SARFESIA Act following a default on a ₹76.24 crore loan from Saraswat Bank. Auditors have consistently flagged concerns regarding the company's ability to continue as a going concern. In the past, the company has also faced regulatory scrutiny, including fines from SEBI related to stock price manipulation.

What changes now

• Shareholders face the prospect of a near-total loss of their investment as the company's operational viability is in question.
• The company's ability to service any debt or meet operational liabilities is severely compromised.
• Potential for liquidation proceedings is high given the admitted terminal state and lack of restructuring hope.
• Creditors and lenders face significant recovery challenges, with assets already seized.

Risks to watch

• Terminal Operational Risk: Management's admission of a 'vitiated' going concern status and 'no hope' for restructuring.
• Asset Seizure: Loss of all property, plants, and equipment under the SARFESIA Act.
• Revenue Collapse: A near-complete evaporation of quarterly revenue.
• Auditor Qualification: Qualified reports signal serious accounting and compliance issues.
• Insolvency Indicators: NPA status and significant debt defaults.

Peer comparison

Nutraplus India operates in the API and pharmaceutical ingredients sector. In stark contrast, major industry peers like Divis Laboratories Ltd. and Dr. Reddy's Laboratories Ltd. are financially robust, possessing substantial borrowing capacity and strong credit ratings. Even smaller players like Ami Organics Ltd. are generally in a much stronger financial position, highlighting Nutraplus India's exceptional distress.

Context metrics (time-bound)

(No specific context metrics from aggregators beyond filing data were deemed necessary or available for this distressed scenario).

What to track next

• Any formal insolvency or liquidation proceedings initiated against the company.
• Outcomes of asset sales or recovery efforts by lenders.
• Further disclosures regarding the company's ability to meet statutory obligations.
• Potential regulatory actions or investigations related to its financial state.
• Any extraordinary general meetings or board resolutions addressing the terminal situation.